Neuromuscular Disorders
Conference Coverage
Myasthenia Gravis: Where Does Traditional Therapy Fit In?
Neurologists debate the data on familiar immunosuppressive agents.
Conference Coverage
New Drug Options Abound for Duchenne Muscular Dystrophy
Mutations are a crucial factor, neurologist says, and steroids still play a role.
Conference Coverage
Neurologists Lack Awareness of Steroid Toxicity
Over 85% of survey respondents indicated that a tool for systematically monitoring corticosteroid toxicity would be valuable.
Conference Coverage
Veterans Affairs Hailed as a ‘Bright Spot’ in ALS Care
Transdisciplinary collaboration is essential for maintaining an effective system.
Conference Coverage
Digital Tool May Help Neurologists Assess Steroid Toxicity
The study results “indicate that patients with MG who initiated steroids demonstrated evidence of steroid toxicity in as little as 90 days after...
Conference Coverage
Remote Assessments: A Win-Win for ALS Patients and Clinics?
Remote monitoring of patients with ALS is a feasible option for both maximizing quality of life and minimizing cost and disruption.
Conference Coverage
Pediatric Myasthenia Gravis: Don’t Treat Children Like Adults
Conference Coverage
New Clinician Tool Aims to Stop ALS Diagnosis Delays
The one-page “thinkALS” tool offers a guide to recognize ALS symptoms and determine when it’s time to refer patients to ALS clinics.
Conference Coverage
Cardiac Monitoring Is Crucial in Neuromuscular Disorder Care
Cardiac conditions can range from asymptomatic to potentially lethal.
Conference Coverage
ALS Update: Drug Therapy Continues to Offer Little Benefit
There’s “a relatively significant additional benefit” to earlier treatment, although patients will vary on whether they think it’s meaningful.
Conference Coverage
Myasthenia Gravis: Similar Symptoms in Relatives Raise Question of Genes